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Abstract Romiplostim is an Fc-peptide fusion protein that
activates intracellular transcriptional pathways via the throm-
bopoietin (TPO) receptor leading to increased platelet produc-
tion. Romiplostim has been engineered to have no amino acid
sequence homology to endogenous TPO. Recombinant
protein therapeutics can be at a risk of development of an
antibody response that can impact efficacy and safety. Hence,
a strategy to detect potential antibody formation to the drug
and to related endogenous molecules can be useful. The
immunogenicity assessment strategy involved both the detec-
tion and characterization of binding and neutralizing anti-
bodies. The method for detection was based on a surface
plasmon resonance biosensor platform using the Biacore
3000. Samples that tested positive for binding antibodies in
the Biacore immunoassay were then tested in a neutralization
assay. Serum samples from 225 subjects with immune
thrombocytopenic purpura (ITP) dosed with romiplostim and
45 ITP subjects dosed with placebo were tested for romiplos-
tim and TPO antibodies. Prior to romiplostim treatment, 17
subjects (7%) tested romiplostim antibody positive and 12
subjects (5%) tested TPO antibody positive for pre-existing
binding antibodies. After romiplostim exposure, 11% of the
subjects exhibited binding antibodies against romiplostim and
5% of the subjects with ITP showed binding antibodies against
TPO. The antibodies against romiplostim did not cross-react
with TPO and vice versa. No cases of anti-TPO neutralizing
antibodies were detected in romiplostim-treated subjects. The
incidence of anti-romiplostim neutralizing antibodies to
romiplostim was 0.4% (one subject); this subject tested
negative at the time of follow-up 4 months later. No impact
on platelet profiles were apparent in subjects that had
antibodies to romiplostim to date. In summary, administration
ofromiplostiminITPsubjectsresultedinthedevelopmentofa
binding antibody response against romiplostim and TPO
ligand.Onesubjectdevelopedaneutralizingantibodyresponse
to romiplostim that impacted the platelet counts of this subject.
No neutralizing antibodies to endogenous TPO were observed.
Keywords Immunethrombocytopenicpurpura(ITP).
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Introduction
Romiplostim (formerly known as AMG 531) is a novel
thrombopoiesis-stimulating protein (peptibody) that binds to
and activates the human thrombopoietin (TPO) receptor leading
to an increase in platelet production. Romiplostim has no amino
acid sequence homology to endogenous TPO [1, 2]. Chronic
immune thrombocytopenic purpura (ITP) is an autoimmune
disorder usually characterized by platelet destruction caused
by anti-platelet antibodies [3–5]. Subjects with this disorder
were administered romiplostim as a potential therapeutic
option for increasing platelet counts in a series of clinical trials.
As with all therapeutic proteins, there is a potential for
subjects to develop antibodies against the therapeutic.
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DOI 10.1007/s00277-010-0908-2Cross-reactive antibodies to PEG-rHuMGDF have led to
thrombocytopenia following administration of multiple
doses of pegylated recombinant human MGDF (PEG-
rHuMGDF) to healthy volunteers and cancer subjects [6–
8]. Hence, when administered romiplostim, subjects might
be at a risk to develop antibodies to romiplostim or cross-
reactive antibodies to TPO. Such cross-reactive antibodies
might be low affinity conformational antibodies that can
still neutralize the endogenous thrombopoietin. To address
this potential concern of immunogenicity, validated assays
that can measure low and high affinity binding and
neutralizing antibodies to romiplostim or TPO were
developed. Utilizing the recommended immunogenicity
assessment strategy [9–11], binding antibodies to romiplos-
tim and/or TPO were monitored throughout the clinical
drug development of romiplostim. In addition, samples
identified positive in these assays were further characterized
by determining their subclasses and affinity [12, 13].
The aim of the study was to assess the presence of these
antibodies to romiplostim and TPO and discuss their possible
impact on platelet levels. The study also discussed the impact
of ITP and its related autoimmune disease status on apparent
induction of an immune response prior to exposure to
romiplostim.
Clinical studies and methods
Immunogenicity to romiplostim was evaluated in two
clinical studies (Phase 1) with healthy subjects (n=56)
and ten clinical studies with ITP subjects (n=235; diag-
nosed per American Society of Hematology guidelines).
Data presented in this paper is from 235 subjects (225
dosed with romiplostim and ten “placebo-only” dosed) who
were evaluated for the presence of antibodies to romiplos-
tim and/or TPO. A total of 45 subjects were initially dosed
with placebo (in the placebo-controlled arm of one Phase 2
and two Phase 3 studies), however, 35 of these subjects
were subsequently dosed with romiplostim in the ongoing
Phase 3 open-label long-term extension study. Therefore,
only ten “placebo-only” dosed subjects remained at the
time of final analysis. The antibodies were assessed prior to
dosing (“pre-existing”) and after dosing (“post-exposure”)
with romiplostim. The strategy for immunogenicity assess-
ment is outlined in Fig. 1.
Biacore immunoassay for binding antibody detection
A surface plasmon resonance (SPR)-based immunoassay
was used for evaluating binding antibodies to romiplostim,
thrombopoietin mimetic peptide (TMP), and TPO [9, 11,
14]. The multiple flow cell SPR-based assays enabled
epitope mapping by assessing the immune reactivity to
either the peptide component TMP or Fc portion of
romiplostim in the same sample [15]. Briefly, romiplostim,
TMP, and TPO were covalently immobilized through free
amines to a carboxy-methylated sensor chip on a Biacore
3000 instrument. Serum samples were diluted to 50% in
TBS-EP sample diluent. Ten microliters of diluted serum
samples and assay controls were individually injected
sequentially across the romiplostim, TMP, and TPO surface
at a rate of 5 µL/min. The samples were confirmed to be
antibodies with a secondary goat anti-human F (ab’)2. The
surfaces were regenerated using guanidine-HCl plus Tween
20. The threshold of the assay was calculated as the upper
bound of a one-sided 95% above a background response
provided by analysis of baselines from 141 subjects with
ITP. Any sample testing at or above threshold was
considered positive, pending additional specificity testing.
Based on titration of the anti-TPO and anti-romiplostim
positive control antibody, the limit of anti-TPO and anti-
romiplostim antibody detection was 200 and 400 ng/mL,
respectively. The specificity of binding to TPO and
romiplostim observed in serum samples was confirmed by
competition through the addition of excess of TPO or
romiplostim to the serum sample before testing. A 50% or
greater reduction in net resonance unit (RU) signal was
required for a positive result for drug specificity. Only
samples that tested above the assay threshold and demon-
strated drug specificity were considered positive for anti-
TPO and/or anti-romiplostim/TMP antibodies.
Biological assay for neutralizing antibody detection
Once the samples were confirmed for binding antibodies, their
neutralizing capability was assessed using a biological assay.
The sensitive neutralizing bioassay utilizes a murine cell line
32Dclone23 transfected with the human thrombopoietin
receptor gene c-mpl. This cell line was maintained in growth
medium supplemented with mIL-3. The 32Dclone23 cells
respond to romiplostim and TPO stimulation by proliferation.
A pre-incubation of romiplostim with anti-romiplostim anti-
bodies blocks the cell proliferation. Similarly, in the TPO
assay, a pre-incubation of TPO with anti-MGDF antibodies
blocks the TPO-induced proliferation. Cells were grown in
absence of mIL-3 overnight. Growth factor-deprived cells
were then incubated with romiplostim or TPO in 1% serum
matrix overnight. The proliferation was measured by
3H-
thymidine uptake. Cut-points were established from 100 ITP
subjects treated with 250 pg/mL romiplostim or 75 pg/mL of
TPO, respectively. These concentrations of romiplostim and
TPO, respectively, demonstrated a tenfold rise above back-
ground and were the most optimal in inducing the prolifer-
ation of cells in the presence of serum from ITP subjects [16].
Samples that tested below the assay cut-points were diluted
and treated with protein G beads, as well as, Sepharose control
S76 Ann Hematol (2010) 89 (Suppl 1):S75–S85beads to confirm that the neutralization was due to immuno-
globulin. After treatment, samples were tested in corresponding
romiplostim or TPO assays in a final 1% serum matrix. A
sample that had 1.9-fold higher counts in protein G-treated
beads than Sepharose-treated beads was confirmed as positive
for neutralizing antibodies. The relative sensitivity of the
r o m i p l o s t i ma n dT P Oa s s a yi s4 00 and 200 ng/mL, respective-
ly, with respect to a polyclonal rabbit anti-romiplostim antibody
and a rabbit anti-megakaryocyte growth and development
factor (anti-MGDF) antibody. The assay parameters for both
binding immunoassay and neutralizing biological assay are
s u m m a r i z e di nT a b l e1.
Statistical analysis
For the binding immunoassay, the ITP specific assay
threshold/baseline was established using mean +3SD and
removal of assay values that are outliers. For non-normally
distributed data, the Box–Cox procedure was used to decide
an appropriate transformation to normality. The upper limit on
the range of the expected values for the population was
determinedbycalculatingtheupperboundofaone-sided95%
prediction interval for the distribution of the assay values.
For the neutralizing bioassays, a cut-point of 99% lower
bound of least square mean was established for the ITP
population. Total assay variance calculated by the analysis
of variance method incorporated subject, day, and plate
differences into the calculation of prediction limits.
Results
Overall immunogenicity of romiplostim in clinical studies
in subjects with ITP
The number of subjects with binding and neutralizing
antibodies to romiplostim and TPO in the clinical studies in
subjects with ITP dosed with romiplostim and placebo,
respectively, are shown in Tables 2 and 3. Clinical efficacy
and safety evaluation in romiplostim-dosed subjects from
five of the ten studies were published by the time of this
analysis. Serum samples from 225 treated ITP subjects
were tested for romiplostim and TPO antibodies prior to
dosing with romiplostim. Seventeen subjects (7%) tested
romiplostim antibody positive and 12 subjects (5%) tested
TPO antibody positive for pre-existing binding antibodies.
3 Drug specificity tests in immunoassay
Screening Immunoassay
TPO, Romiplostim and Peptide Only 1
2
Confirmation required for samples with
signal above assay thresholds
Below assay thresholds
(no further testing)
No further testing
4 Neutralizing Antibody Bioassays
Positive for Neutralizing Antibody
Positive for pre-existingAb or post-exposureAb
Fig. 1 Process for assessment of immunogenicity in the romiplostim
clinical trial program. The strategy for immunogenicity assessment
involved a screening step where the serum samples were assessed for
their ability to bind to TPO, romiplostim, and peptide component of
romiplostim. If the sample showed binding above the validated assay
threshold, it was further confirmed in a specificity test. Based on the
reactivityobserved,excessoftherelevantTPOorromiplostimwasadded
to the reactive sample and assessed for neutralization of the reactive
response. If the sample exhibited more than 50% depletion of signal in
drug specificity analysis, the sample was then confirmed for its ability to
neutralize romiplostim or TPO in a biological functional assay
Table 1 Summary of assay parameters for immunoassay and bioassay
Immunoassay Bioassay
Romiplostim TPO Romiplostim TPO
Assay sensitivity (ng/mL) 400 200 400 200
Specificity/confirmatory Depletion >50% with 6.4 µg/mL of drug/ligand Depletion >48% with protein G
Drug tolerance (ng/mL) 10 10 25 6.3
Ann Hematol (2010) 89 (Suppl 1):S75–S85 S77Following dosing with romiplostim, 25 out of 225 (11%)
subjects with ITP exhibited binding antibodies against
romiplostim and 12 out of 225 (5%) subjects with ITP
showed binding antibodies against TPO. These subjects
were not positive for antibodies to either romiplostim or
TPO prior to exposure to the drug.
A total of 45 placebo subjects were evaluated for pre-
existing antibodies to romiplostim and TPO. Four of the 45
subjects (9%) were positive for binding antibodies to
romiplostim and six of 45 (13%) subjects were positive
for binding antibodies to TPO (Table 3).
A total of 56 healthy subjects were evaluated for binding
and neutralizing antibodies to romiplostim and TPO in two
Phase 1 clinical studies. Two of the 56 subjects (4%) were
positive for pre-existing antibodies to romiplostim and three
of 56 subjects (5%) were positive for pre-existing anti-
bodies to TPO. Following exposure to romiplostim, one of
the 56 subjects developed binding antibodies to romiplos-
tim (2%) and another one of 56 subjects developed binding
antibodies to TPO (2%; Fig. 2).
Neutralizingantibodiestoromiplostimweredetectedinone
subject out of 225 (0.4%) subjects with ITP who were treated
with romiplostim. This specific subject was first enrolled in a
Phase 1–2 multicenter, open-label, unit dose-finding study of
safety and efficacy of romiplostim in adult ITP subjects. The
subjecthada history of splenectomyandreceivedromiplostim
at unit doses of 100 µg (equivalent to 1.06 µg/kg injection) on
days 1 and 22 of this study. Their baseline platelet count at the
time of initial enrollment was 31 × 10
9/L. The subject
completed the study per protocol, with platelet counts ranging
from 25 to 110 × 10
9/L. Blood samples obtained at baseline,
on day 29, and on day 78 end of study (EOS) were negative
for both anti-romiplostim and anti-TPO neutralizing anti-
bodies. The same subject was enrolled 21 months later in an
ongoing long-term extension study. Baseline platelet counts
at the time of enrollment were 24 × 10
9/L. The subject was
started on a romiplostim dose of 1 µg/kg and from week 2
until week 77, the dose was kept at 2 or 3 µg/kg. The dose
was tapered off to 1 µg/kg at week 78 based on the subject’s
request to discontinue the medication. At no time during
weeks 2 to 79 were the subject’s platelet counts below the
baseline (week 1) value of 24 × 10
9/L. The subject did not
receive any ITP rescue medications during this time.
In the long-term extension study, antibodies were assessed
at pre-dose and every 12 weeks during romiplostim treatment
until EOS. The subject was negative for binding antibodies to
romiplostimorTPOuntilweek12.Thesubjectfirstdeveloped
binding antibodies to romiplostim at week 36, but was
negative for neutralizing antibodies. The platelet counts were
in the range of 101 to 291 × 10
9/L from week 3 to week 40.
Blood samples obtained at week 60 and at week 66 were
positive for anti-romiplostim binding antibodies, but were
negative for anti-romiplostim neutralizing antibodies. The
platelet counts from week 41 to week 55 and from week 56
to week 78 were in the range of 42 to 106 × 10
9/L and in the
range of 43 to 87 × 10
9/L, respectively. The blood sample
obtained at week 79 (EOS) was positive for anti-romiplostim
binding and neutralizing antibodies. At week 78 and at
week 79/EOS, the platelet counts were 76 × 10
9/L and
37 × 10
9/L, respectively. A follow-up blood sample, obtained
about 4 months after the week 79/EOS, tested positive for
anti-romiplostim binding antibodies, but negative for anti-
romiplostim neutralizing antibodies. No binding or neutral-
izing antibodies to TPO were detected at any time-point. No
platelet counts were assessed during follow-up at 4 months as
the subject had discontinued the study (Fig. 3a).
One subject (from the Phase III study in non-splenectomized
subjects) was positive for neutralizing antibodies to TPO at
baseline (prior to romiplostim exposure); however, all of the
post-dose sample time-points for the subject were negative for
binding antibodies. This subject did not exhibit any clinical
sequelae and there appears to be no impact on the platelet
counts pre- or post-dosing with romiplostim (Fig. 3b).
Impact of immunogenicity on pharmacodynamics
The impact of binding antibodies on platelet counts was
analyzed by longitudinal analyses (antibody time-point versus
platelet counts) of all subjects in the studies [17–19]. The
median platelet count profiles in the antibody positive subjects
were very similar to the subjects that did not demonstrate
post-exposure binding antibodies. Analyses of all the subjects
with binding antibodies to romiplostim or TPO did not appear
to have any impact on platelet profiles and the median platelet
counts were maintained at ≥50 × 10
9/L for all romiplostim-
treated subjects (data not shown).
Cross-reactive antibodies to TPO
Both the romiplostim- and placebo-dosed groups of ITP
subjects exhibited anti-TPO binding antibodies (Tables 2
and 3). Anti-TPO binding antibodies were also observed in
a small proportion of healthy subjects (Fig. 2). All subjects
that demonstrated binding antibodies to romiplostim fol-
lowing dosing with romiplostim were tested for cross-
reactivity to TPO, and all the subjects with TPO positive
samples were tested for cross-reactivity to romiplostim. No
cross-reactivity was observed.
Discussion
We have assessed the immunogenicity of romiplostim, an
efficacious therapeutic protein approved for the treatment of
chronic ITP [17, 20]. The ability to detect low affinity
immune responses allows for a better understanding of the
S78 Ann Hematol (2010) 89 (Suppl 1):S75–S85T
a
b
l
e
2
I
n
c
i
d
e
n
c
e
o
f
b
i
n
d
i
n
g
a
n
d
n
e
u
t
r
a
l
i
z
i
n
g
a
n
t
i
b
o
d
i
e
s
t
o
r
o
m
i
p
l
o
s
t
i
m
a
n
d
t
h
r
o
m
b
o
p
o
i
e
t
i
n
i
n
s
u
b
j
e
c
t
s
r
e
c
e
i
v
i
n
g
r
o
m
i
p
l
o
s
t
i
m
S
t
u
d
y
d
e
s
c
r
i
p
t
i
o
n
T
o
t
a
l
s
u
b
j
e
c
t
s
T
r
e
a
t
m
e
n
t
r
e
g
i
m
e
n
A
n
t
i
b
o
d
y
a
s
s
e
s
s
m
e
n
t
t
i
m
e
-
p
o
i
n
t
s
P
r
e
-
e
x
i
s
t
i
n
g
a
n
t
i
b
o
d
y
a
t
o
r
o
m
i
p
l
o
s
t
i
m
(
n
,
%
)
P
o
s
t
-
e
x
p
o
s
u
r
e
a
n
t
i
b
o
d
y
b
r
e
s
p
o
n
s
e
t
o
r
o
m
i
p
l
o
s
t
i
m
(
n
,
%
)
P
r
e
-
e
x
i
s
t
i
n
g
a
n
t
i
b
o
d
y
a
t
o
t
h
r
o
m
b
o
p
o
i
e
t
i
n
(
n
,
%
)
P
o
s
t
-
e
x
p
o
s
u
r
e
a
n
t
i
b
o
d
y
r
e
s
p
o
n
s
e
b
t
o
t
h
r
o
m
b
o
p
o
i
e
t
i
n
(
n
,
%
)
N
e
u
t
r
a
l
i
z
i
n
g
a
n
t
i
b
o
d
y
r
e
s
p
o
n
s
e
t
o
r
o
m
i
p
l
o
s
t
i
m
/
T
P
O
(
n
,
%
)
P
h
a
s
e
1
–
2
,
m
u
l
t
i
c
e
n
t
e
r
,
o
p
e
n
-
l
a
b
e
l
,
d
o
s
e
-
f
i
n
d
i
n
g
,
s
e
q
u
e
n
t
i
a
l
-
c
o
h
o
r
t
s
t
u
d
y
e
v
a
l
u
a
t
i
n
g
t
h
e
s
a
f
e
t
y
a
n
d
e
f
f
i
c
a
c
y
o
f
r
o
m
i
p
l
o
s
t
i
m
i
n
t
h
r
o
m
b
o
c
y
t
o
p
e
n
i
c
s
u
b
j
e
c
t
s
w
i
t
h
I
T
P
2
4
S
C
d
o
s
e
s
o
f
r
o
m
i
p
l
o
s
t
i
m
a
t
0
.
2
,
0
.
5
,
1
.
0
,
3
.
0
,
6
.
0
,
o
r
1
0
µ
g
/
k
g
;
s
u
b
j
e
c
t
s
i
n
e
a
c
h
d
o
s
e
c
o
h
o
r
t
r
e
c
e
i
v
e
d
s
e
c
o
n
d
d
o
s
e
a
t
d
a
y
1
5
o
r
d
a
y
2
2
i
f
p
l
a
t
e
l
e
t
c
o
u
n
t
s
w
e
r
e
<
5
0
×
1
0
9
/
L
P
r
e
-
d
o
s
e
,
w
e
e
k
4
a
n
d
w
e
e
k
1
1
2
(
8
)
0
(
0
)
0
(
0
)
0
(
0
)
0
(
0
)
P
h
a
s
e
2
,
m
u
l
t
i
c
e
n
t
e
r
,
r
a
n
d
o
m
i
z
e
d
,
d
o
s
e
-
f
i
n
d
i
n
g
,
p
l
a
c
e
b
o
-
c
o
n
t
r
o
l
l
e
d
s
t
u
d
y
e
v
a
l
u
a
t
i
n
g
s
a
f
e
t
y
,
P
K
/
P
D
,
a
n
d
e
f
f
i
c
a
c
y
o
f
r
o
m
i
p
l
o
s
t
i
m
i
n
t
h
r
o
m
b
o
c
y
t
o
p
e
n
i
c
s
u
b
j
e
c
t
s
w
i
t
h
I
T
P
1
7
T
w
o
p
a
r
a
l
l
e
l
r
o
m
i
p
l
o
s
t
i
m
d
o
s
a
g
e
c
o
h
o
r
t
s
(
1
.
0
µ
g
/
k
g
o
r
3
.
0
µ
g
/
k
g
S
C
w
e
e
k
l
y
f
o
r
6
w
e
e
k
s
)
P
r
e
-
d
o
s
e
,
w
e
e
k
7
a
n
d
w
e
e
k
1
1
0
(
0
)
0
(
0
)
0
(
0
)
0
(
0
)
0
(
0
)
P
h
a
s
e
1
–
2
,
m
u
l
t
i
c
e
n
t
e
r
,
o
p
e
n
-
l
a
b
e
l
,
s
e
q
u
e
n
t
i
a
l
-
c
o
h
o
r
t
,
u
n
i
t
d
o
s
e
-
f
i
n
d
i
n
g
s
t
u
d
y
o
f
s
a
f
e
t
y
a
n
d
e
f
f
i
c
a
c
y
o
f
r
o
m
i
p
l
o
s
t
i
m
i
n
a
d
u
l
t
t
h
r
o
m
b
o
c
y
t
o
p
e
n
i
c
s
u
b
j
e
c
t
s
w
i
t
h
I
T
P
1
6
S
C
u
n
i
t
d
o
s
e
s
o
f
r
o
m
i
p
l
o
s
t
i
m
(
3
0
,
1
0
0
,
3
0
0
,
o
r
5
0
0
µ
g
.
S
u
b
j
e
c
t
s
i
n
e
a
c
h
d
o
s
e
c
o
h
o
r
t
r
e
c
e
i
v
e
d
a
s
e
c
o
n
d
d
o
s
e
a
t
d
a
y
1
5
o
r
d
a
y
2
2
i
f
p
l
a
t
e
l
e
t
c
o
u
n
t
s
w
e
r
e
<
5
0
×
1
0
9
/
L
,
t
h
e
n
w
e
r
e
o
b
s
e
r
v
e
d
f
o
r
8
w
e
e
k
s
P
r
e
-
d
o
s
e
,
w
e
e
k
4
a
n
d
w
e
e
k
1
1
0
(
0
)
0
(
0
)
1
(
6
)
0
(
0
)
0
(
0
)
P
h
a
s
e
2
,
m
u
l
t
i
c
e
n
t
e
r
,
o
p
e
n
-
l
a
b
e
l
,
d
o
s
e
-
e
s
c
a
l
a
t
i
o
n
,
s
e
q
u
e
n
t
i
a
l
-
c
o
h
o
r
t
,
s
a
f
e
t
y
a
n
d
e
f
f
i
c
a
c
y
(
p
l
a
t
e
l
e
t
r
e
s
p
o
n
s
e
)
i
n
t
h
r
o
m
b
o
c
y
t
o
p
e
n
i
c
s
u
b
j
e
c
t
s
w
i
t
h
I
T
P
i
n
J
a
p
a
n
1
2
1
,
3
,
o
r
6
µ
g
/
k
g
S
C
w
e
e
k
l
y
f
o
r
2
w
e
e
k
s
.
S
u
b
j
e
c
t
s
a
c
h
i
e
v
i
n
g
a
p
l
a
t
e
l
e
t
r
e
s
p
o
n
s
e
m
a
y
e
n
t
e
r
c
o
n
t
i
n
u
a
t
i
o
n
p
h
a
s
e
a
n
d
r
e
c
e
i
v
e
w
e
e
k
l
y
S
C
i
n
j
e
c
t
i
o
n
s
a
t
t
h
e
i
r
o
r
i
g
i
n
a
l
d
o
s
e
s
P
r
e
-
d
o
s
e
,
w
e
e
k
7
,
w
e
e
k
1
5
,
a
n
d
w
e
e
k
2
4
(
e
n
d
o
f
s
t
u
d
y
)
0
(
0
)
0
(
0
)
0
(
0
)
0
(
0
)
0
(
0
)
P
i
v
o
t
a
l
,
p
h
a
s
e
3
,
r
a
n
d
o
m
i
z
e
d
,
d
o
u
b
l
e
-
b
l
i
n
d
,
p
l
a
c
e
b
o
-
c
o
n
t
r
o
l
l
e
d
,
2
4
-
w
e
e
k
s
t
u
d
y
t
o
a
s
s
e
s
s
e
f
f
i
c
a
c
y
(
p
l
a
t
e
l
e
t
r
e
s
p
o
n
s
e
)
a
n
d
s
a
f
e
t
y
i
n
t
r
e
a
t
i
n
g
a
d
u
l
t
t
h
r
o
m
b
o
c
y
t
o
p
e
n
i
c
s
u
b
j
e
c
t
s
w
i
t
h
I
T
P
w
h
o
h
a
v
e
n
o
t
y
e
t
u
n
d
e
r
g
o
n
e
s
p
l
e
n
e
c
t
o
m
y
4
2
1
t
o
1
5
µ
g
/
k
g
S
C
;
w
e
e
k
l
y
d
o
s
i
n
g
,
a
d
j
u
s
t
e
d
o
n
t
h
e
b
a
s
i
s
o
f
p
l
a
t
e
l
e
t
c
o
u
n
t
s
f
o
r
2
4
w
e
e
k
s
P
r
e
-
d
o
s
e
,
w
e
e
k
9
,
w
e
e
k
1
7
,
a
n
d
w
e
e
k
2
4
(
e
n
d
o
f
s
t
u
d
y
)
4
(
1
0
)
1
(
2
)
3
(
7
)
0
(
0
)
0
(
0
)
P
i
v
o
t
a
l
,
p
h
a
s
e
3
,
r
a
n
d
o
m
i
z
e
d
,
d
o
u
b
l
e
-
b
l
i
n
d
,
p
l
a
c
e
b
o
-
c
o
n
t
r
o
l
l
e
d
,
2
4
-
w
e
e
k
s
t
u
d
y
t
o
a
s
s
e
s
s
e
f
f
i
c
a
c
y
(
d
u
r
a
b
l
e
p
l
a
t
e
l
e
t
r
e
s
p
o
n
s
e
)
a
n
d
s
a
f
e
t
y
i
n
t
r
e
a
t
i
n
g
a
d
u
l
t
t
h
r
o
m
b
o
c
y
t
o
p
e
n
i
c
s
u
b
j
e
c
t
s
w
i
t
h
I
T
P
r
e
f
r
a
c
t
o
r
y
t
o
s
p
l
e
n
e
c
t
o
m
y
4
2
1
t
o
1
5
µ
g
/
k
g
S
C
;
w
e
e
k
l
y
d
o
s
i
n
g
,
a
d
j
u
s
t
e
d
o
n
t
h
e
b
a
s
i
s
o
f
p
l
a
t
e
l
e
t
c
o
u
n
t
s
µ
g
/
k
g
)
,
f
o
r
2
4
w
e
e
k
s
P
r
e
-
d
o
s
e
,
w
e
e
k
9
,
w
e
e
k
1
7
,
a
n
d
w
e
e
k
2
4
(
e
n
d
o
f
s
t
u
d
y
)
1
(
2
)
3
(
7
)
2
(
5
)
2
(
5
)
0
(
0
)
O
p
e
n
-
l
a
b
e
l
s
t
u
d
y
o
f
r
o
m
i
p
l
o
s
t
i
m
i
n
t
h
r
o
m
b
o
c
y
t
o
p
e
n
i
c
a
d
u
l
t
s
u
b
j
e
c
t
s
w
i
t
h
I
T
P
w
h
o
h
a
v
e
r
e
c
e
i
v
e
d
a
t
l
e
a
s
t
o
n
e
p
r
i
o
r
t
h
e
r
a
p
y
f
o
r
I
T
P
2
8
3
t
o
1
0
µ
g
/
k
g
S
C
;
w
e
e
k
l
y
d
o
s
i
n
g
,
a
d
j
u
s
t
e
d
o
n
t
h
e
b
a
s
i
s
o
f
p
l
a
t
e
l
e
t
c
o
u
n
t
s
P
r
e
-
d
o
s
e
a
n
d
e
v
e
r
y
1
2
w
e
e
k
s
a
t
t
r
e
a
t
m
e
n
t
c
y
c
l
e
t
i
l
l
e
n
d
o
f
s
t
u
d
y
1
(
4
)
3
(
1
1
)
1
(
4
)
2
(
7
)
0
(
0
)
P
h
a
s
e
3
,
o
p
e
n
-
l
a
b
e
l
,
e
x
t
e
n
s
i
o
n
s
t
u
d
y
t
o
a
s
s
e
s
s
l
o
n
g
-
t
e
r
m
d
o
s
i
n
g
o
f
r
o
m
i
p
l
o
s
t
i
m
i
n
a
d
u
l
t
a
n
d
p
e
d
i
a
t
r
i
c
s
u
b
j
e
c
t
s
w
i
t
h
I
T
P
w
h
o
p
r
e
v
i
o
u
s
l
y
p
a
r
t
i
c
i
p
a
t
e
d
i
n
r
o
m
i
p
l
o
s
t
i
m
s
t
u
d
i
e
s
1
4
1
c
1
t
o
1
0
µ
g
/
k
g
S
C
;
w
e
e
k
l
y
d
o
s
i
n
g
,
a
d
j
u
s
t
e
d
o
n
t
h
e
b
a
s
i
s
o
f
p
l
a
t
e
l
e
t
c
o
u
n
t
s
P
r
e
-
d
o
s
e
a
n
d
e
v
e
r
y
1
2
w
e
e
k
s
a
t
t
r
e
a
t
m
e
n
t
c
y
c
l
e
t
i
l
l
e
n
d
o
f
s
t
u
d
y
9
(
6
)
1
5
(
1
1
)
7
(
5
)
7
(
5
)
1
(
0
.
7
—
R
o
m
i
p
l
o
s
t
i
m
)
O
p
e
n
-
l
a
b
e
l
,
p
h
a
s
e
3
b
e
f
f
i
c
a
c
y
a
n
d
1
0
3
t
o
1
0
µ
g
/
k
g
S
C
;
w
e
e
k
l
y
d
o
s
i
n
g
,
P
r
e
-
d
o
s
e
a
n
d
e
v
e
r
y
1
(
1
0
)
1
(
1
0
)
0
(
0
)
1
(
1
0
)
0
(
0
)
Ann Hematol (2010) 89 (Suppl 1):S75–S85 S79T
a
b
l
e
2
(
c
o
n
t
i
n
u
e
d
)
S
t
u
d
y
d
e
s
c
r
i
p
t
i
o
n
T
o
t
a
l
s
u
b
j
e
c
t
s
T
r
e
a
t
m
e
n
t
r
e
g
i
m
e
n
A
n
t
i
b
o
d
y
a
s
s
e
s
s
m
e
n
t
t
i
m
e
-
p
o
i
n
t
s
P
r
e
-
e
x
i
s
t
i
n
g
a
n
t
i
b
o
d
y
a
t
o
r
o
m
i
p
l
o
s
t
i
m
(
n
,
%
)
P
o
s
t
-
e
x
p
o
s
u
r
e
a
n
t
i
b
o
d
y
b
r
e
s
p
o
n
s
e
t
o
r
o
m
i
p
l
o
s
t
i
m
(
n
,
%
)
P
r
e
-
e
x
i
s
t
i
n
g
a
n
t
i
b
o
d
y
a
t
o
t
h
r
o
m
b
o
p
o
i
e
t
i
n
(
n
,
%
)
P
o
s
t
-
e
x
p
o
s
u
r
e
a
n
t
i
b
o
d
y
r
e
s
p
o
n
s
e
b
t
o
t
h
r
o
m
b
o
p
o
i
e
t
i
n
(
n
,
%
)
N
e
u
t
r
a
l
i
z
i
n
g
a
n
t
i
b
o
d
y
r
e
s
p
o
n
s
e
t
o
r
o
m
i
p
l
o
s
t
i
m
/
T
P
O
(
n
,
%
)
t
o
l
e
r
a
b
i
l
i
t
y
s
t
u
d
y
e
v
a
l
u
a
t
i
n
g
r
o
m
i
p
l
o
s
t
i
m
a
g
a
i
n
s
t
m
e
d
i
c
a
l
s
t
a
n
d
a
r
d
o
f
c
a
r
e
(
S
O
C
)
i
n
n
o
n
-
s
p
l
e
n
e
c
t
o
m
i
z
e
d
p
a
t
i
e
n
t
s
a
d
j
u
s
t
e
d
o
n
t
h
e
b
a
s
i
s
o
f
p
l
a
t
e
l
e
t
c
o
u
n
t
s
1
2
w
e
e
k
s
a
t
t
r
e
a
t
m
e
n
t
c
y
c
l
e
t
i
l
l
e
n
d
o
f
s
t
u
d
y
O
p
e
n
-
l
a
b
e
l
e
x
t
e
n
s
i
o
n
s
t
u
d
y
t
o
a
s
s
e
s
s
l
o
n
g
-
t
e
r
m
d
o
s
i
n
g
o
f
r
o
m
i
p
l
o
s
t
i
m
i
n
J
a
p
a
n
e
s
e
s
u
b
j
e
c
t
s
w
i
t
h
I
T
P
w
h
o
p
r
e
v
i
o
u
s
l
y
p
a
r
t
i
c
i
p
a
t
e
d
i
n
r
o
m
i
p
l
o
s
t
i
m
s
t
u
d
i
e
s
1
1
d
3
t
o
1
0
µ
g
/
k
g
S
C
;
w
e
e
k
l
y
d
o
s
i
n
g
,
a
d
j
u
s
t
e
d
o
n
t
h
e
b
a
s
i
s
o
f
p
l
a
t
e
l
e
t
c
o
u
n
t
s
P
r
e
-
d
o
s
e
a
n
d
e
v
e
r
y
1
2
w
e
e
k
s
a
t
t
r
e
a
t
m
e
n
t
c
y
c
l
e
t
i
l
l
e
n
d
o
f
s
t
u
d
y
0
(
0
)
2
(
1
8
)
0
(
0
)
0
(
0
)
0
(
0
)
T
o
t
a
l
(
s
u
m
o
f
a
l
l
s
t
u
d
i
e
s
)
2
2
5
1
7
e
(
7
)
2
5
(
1
1
)
1
2
e
(
5
)
1
2
(
5
)
1
(
0
.
4
)
I
T
P
i
m
m
u
n
e
(
i
d
i
o
p
a
t
h
i
c
)
t
h
r
o
m
b
o
c
y
t
o
p
e
n
i
c
p
u
r
p
u
r
a
,
I
V
i
n
t
r
a
v
e
n
o
u
s
,
P
D
p
h
a
r
m
a
c
o
d
y
n
a
m
i
c
(
s
)
,
P
K
p
h
a
r
m
a
c
o
k
i
n
e
t
i
c
(
s
)
,
S
C
s
u
b
c
u
t
a
n
e
o
u
s
,
T
P
O
t
h
r
o
m
b
o
p
o
i
e
t
i
n
a
P
r
e
-
e
x
i
s
t
i
n
g
a
n
t
i
b
o
d
i
e
s
t
o
r
o
m
i
p
l
o
s
t
i
m
o
r
T
P
O
i
n
c
l
u
d
e
s
u
b
j
e
c
t
s
w
h
o
h
a
d
a
n
t
i
b
o
d
i
e
s
p
r
i
o
r
t
o
a
d
m
i
n
i
s
t
r
a
t
i
o
n
o
f
r
o
m
i
p
l
o
s
t
i
m
.
S
o
m
e
o
f
t
h
e
s
e
s
u
b
j
e
c
t
s
c
o
n
t
i
n
u
e
d
t
o
p
e
r
s
i
s
t
e
v
e
n
a
f
t
e
r
r
o
m
i
p
l
o
s
t
i
m
d
o
s
i
n
g
a
n
d
w
e
r
e
c
o
n
s
i
d
e
r
e
d
p
r
e
-
e
x
i
s
t
i
n
g
.
b
P
o
s
t
-
e
x
p
o
s
u
r
e
a
n
t
i
b
o
d
i
e
s
t
o
r
o
m
i
p
l
o
s
t
i
m
o
r
T
P
O
i
n
c
l
u
d
e
d
s
u
b
j
e
c
t
s
w
h
o
h
a
d
a
n
t
i
b
o
d
i
e
s
f
o
l
l
o
w
i
n
g
d
o
s
i
n
g
w
i
t
h
r
o
m
i
p
l
o
s
t
i
m
.
c
O
n
e
h
u
n
d
r
e
d
s
e
v
e
n
o
f
t
h
e
1
4
1
s
u
b
j
e
c
t
s
r
o
l
l
e
d
o
v
e
r
f
r
o
m
e
a
r
l
i
e
r
p
a
r
e
n
t
s
t
u
d
i
e
s
(
e
x
c
e
p
t
t
h
e
d
o
s
e
-
f
i
n
d
i
n
g
s
t
u
d
y
i
n
J
a
p
a
n
)
a
n
d
h
e
n
c
e
w
e
r
e
n
o
t
c
o
u
n
t
e
d
t
w
i
c
e
.
T
h
e
p
e
r
c
e
n
t
i
n
c
i
d
e
n
c
e
i
s
b
a
s
e
d
o
n
a
l
l
s
u
b
j
e
c
t
s
i
n
t
h
e
s
t
u
d
y
.
d
A
l
l
1
1
s
u
b
j
e
c
t
s
r
o
l
l
e
d
o
v
e
r
f
r
o
m
P
h
a
s
e
I
I
s
a
f
e
t
y
/
d
o
s
e
-
f
i
n
d
i
n
g
s
t
u
d
y
i
n
J
a
p
a
n
a
n
d
h
e
n
c
e
w
e
r
e
n
o
t
c
o
u
n
t
e
d
t
w
i
c
e
i
n
o
v
e
r
a
l
l
i
n
c
i
d
e
n
c
e
.
e
O
f
t
h
e
1
8
s
u
b
j
e
c
t
s
i
n
t
h
i
s
g
r
o
u
p
,
o
n
e
s
u
b
j
e
c
t
w
i
t
h
p
r
e
-
e
x
i
s
t
i
n
g
a
n
t
i
b
o
d
i
e
s
t
o
r
o
m
i
p
l
o
s
t
i
m
r
o
l
l
e
d
o
v
e
r
f
r
o
m
a
p
a
r
e
n
t
s
t
u
d
y
i
n
t
o
t
h
e
r
o
l
l
-
o
v
e
r
e
x
t
e
n
s
i
o
n
s
t
u
d
y
,
h
e
n
c
e
t
h
i
s
s
u
b
j
e
c
t
w
a
s
o
n
l
y
c
o
u
n
t
e
d
o
n
c
e
i
n
t
h
e
t
o
t
a
l
i
n
c
i
d
e
n
c
e
.
S
i
m
i
l
a
r
l
y
,
o
f
t
h
e
1
4
s
u
b
j
e
c
t
s
,
t
w
o
s
u
b
j
e
c
t
s
w
i
t
h
p
r
e
-
e
x
i
s
t
i
n
g
a
n
t
i
b
o
d
i
e
s
t
o
T
P
O
r
o
l
l
e
d
o
v
e
r
f
r
o
m
t
h
e
i
r
r
e
s
p
e
c
t
i
v
e
p
a
r
e
n
t
s
t
u
d
i
e
s
t
o
r
o
l
l
-
o
v
e
r
e
x
t
e
n
s
i
o
n
s
t
u
d
y
,
h
e
n
c
e
t
h
e
s
e
s
u
b
j
e
c
t
s
w
e
r
e
c
o
u
n
t
e
d
o
n
l
y
o
n
c
e
i
n
t
h
e
t
o
t
a
l
i
n
c
i
d
e
n
c
e
.
S80 Ann Hematol (2010) 89 (Suppl 1):S75–S85T
a
b
l
e
3
I
n
c
i
d
e
n
c
e
o
f
b
i
n
d
i
n
g
a
n
d
n
e
u
t
r
a
l
i
z
i
n
g
a
n
t
i
b
o
d
i
e
s
t
o
r
o
m
i
p
l
o
s
t
i
m
a
n
d
t
h
r
o
m
b
o
p
o
i
e
t
i
n
i
n
p
l
a
c
e
b
o
-
d
o
s
e
d
s
u
b
j
e
c
t
s
S
t
u
d
y
d
e
s
c
r
i
p
t
i
o
n
T
o
t
a
l
s
u
b
j
e
c
t
s
T
r
e
a
t
m
e
n
t
r
e
g
i
m
e
n
A
n
t
i
b
o
d
y
a
s
s
e
s
s
m
e
n
t
t
i
m
e
-
p
o
i
n
t
s
N
u
m
b
e
r
o
f
s
u
b
j
e
c
t
s
w
i
t
h
p
r
e
-
e
x
i
s
t
i
n
g
a
n
t
i
b
o
d
y
t
o
r
o
m
i
p
l
o
s
t
i
m
a
(
n
,
i
n
c
i
d
e
n
c
e
,
%
)
N
u
m
b
e
r
o
f
s
u
b
j
e
c
t
s
w
i
t
h
p
r
e
-
e
x
i
s
t
i
n
g
a
n
t
i
b
o
d
y
t
o
t
h
r
o
m
b
o
p
o
e
t
i
n
a
(
n
,
i
n
c
i
d
e
n
c
e
,
%
)
N
u
m
b
e
r
o
f
s
u
b
j
e
c
t
s
w
i
t
h
n
e
u
t
r
a
l
i
z
i
n
g
a
n
t
i
b
o
d
y
r
e
s
p
o
n
s
e
t
o
t
h
r
o
m
b
o
p
o
e
t
i
n
(
n
,
i
n
c
i
d
e
n
c
e
,
%
)
N
e
u
t
r
a
l
i
z
i
n
g
a
n
t
i
b
o
d
y
r
e
s
p
o
n
s
e
t
o
r
o
m
i
p
l
o
s
t
i
m
/
T
P
O
(
n
,
i
n
c
i
d
e
n
c
e
,
%
)
P
h
a
s
e
2
,
m
u
l
t
i
c
e
n
t
e
r
,
r
a
n
d
o
m
i
z
e
d
,
d
o
s
e
-
f
i
n
d
i
n
g
,
p
l
a
c
e
b
o
-
c
o
n
t
r
o
l
l
e
d
s
t
u
d
y
e
v
a
l
u
a
t
i
n
g
s
a
f
e
t
y
,
P
K
/
P
D
,
a
n
d
e
f
f
i
c
a
c
y
o
f
r
o
m
i
p
l
o
s
t
i
m
i
n
t
h
r
o
m
b
o
c
y
t
o
p
e
n
i
c
s
u
b
j
e
c
t
s
w
i
t
h
I
T
P
4
S
C
d
o
s
e
s
o
f
r
o
m
i
p
l
o
s
t
i
m
a
t
0
.
2
,
0
.
5
,
1
.
0
,
3
.
0
,
6
.
0
,
o
r
1
0
µ
g
/
k
g
;
s
u
b
j
e
c
t
s
i
n
e
a
c
h
d
o
s
e
c
o
h
o
r
t
r
e
c
e
i
v
e
d
s
e
c
o
n
d
d
o
s
e
a
t
d
a
y
1
5
o
r
d
a
y
2
2
i
f
p
l
a
t
e
l
e
t
c
o
u
n
t
s
w
e
r
e
<
5
0
×
1
0
9
/
L
P
r
e
-
d
o
s
e
,
w
e
e
k
4
a
n
d
w
e
e
k
1
1
0
(
0
)
0
(
0
)
0
(
0
)
0
(
0
)
P
i
v
o
t
a
l
,
p
h
a
s
e
3
,
r
a
n
d
o
m
i
z
e
d
,
d
o
u
b
l
e
-
b
l
i
n
d
,
p
l
a
c
e
b
o
-
c
o
n
t
r
o
l
l
e
d
,
2
4
-
w
e
e
k
s
t
u
d
y
t
o
a
s
s
e
s
s
e
f
f
i
c
a
c
y
(
p
l
a
t
e
l
e
t
r
e
s
p
o
n
s
e
)
a
n
d
s
a
f
e
t
y
i
n
t
r
e
a
t
i
n
g
a
d
u
l
t
t
h
r
o
m
b
o
c
y
t
o
p
e
n
i
c
s
u
b
j
e
c
t
s
w
i
t
h
I
T
P
w
h
o
h
a
v
e
n
o
t
y
e
t
u
n
d
e
r
g
o
n
e
s
p
l
e
n
e
c
t
o
m
y
2
1
1
t
o
1
5
µ
g
/
k
g
S
C
;
w
e
e
k
l
y
d
o
s
i
n
g
,
a
d
j
u
s
t
e
d
o
n
t
h
e
b
a
s
i
s
o
f
p
l
a
t
e
l
e
t
c
o
u
n
t
s
f
o
r
2
4
w
e
e
k
s
P
r
e
-
d
o
s
e
,
w
e
e
k
9
,
w
e
e
k
1
7
,
a
n
d
w
e
e
k
2
4
(
e
n
d
o
f
s
t
u
d
y
)
2
(
1
0
)
2
(
1
0
)
0
(
0
)
0
(
0
)
P
i
v
o
t
a
l
,
p
h
a
s
e
3
,
r
a
n
d
o
m
i
z
e
d
,
d
o
u
b
l
e
-
b
l
i
n
d
,
p
l
a
c
e
b
o
-
c
o
n
t
r
o
l
l
e
d
,
2
4
-
w
e
e
k
s
t
u
d
y
t
o
a
s
s
e
s
s
e
f
f
i
c
a
c
y
(
d
u
r
a
b
l
e
p
l
a
t
e
l
e
t
r
e
s
p
o
n
s
e
)
a
n
d
s
a
f
e
t
y
i
n
t
r
e
a
t
i
n
g
a
d
u
l
t
t
h
r
o
m
b
o
c
y
t
o
p
e
n
i
c
s
u
b
j
e
c
t
s
w
i
t
h
I
T
P
r
e
f
r
a
c
t
o
r
y
t
o
s
p
l
e
n
e
c
t
o
m
y
2
0
1
t
o
1
5
µ
g
/
k
g
S
C
;
w
e
e
k
l
y
d
o
s
i
n
g
,
a
d
j
u
s
t
e
d
o
n
t
h
e
b
a
s
i
s
o
f
p
l
a
t
e
l
e
t
c
o
u
n
t
s
µ
g
/
k
g
)
,
f
o
r
2
4
w
e
e
k
s
P
r
e
-
d
o
s
e
,
w
e
e
k
9
,
w
e
e
k
1
7
,
a
n
d
w
e
e
k
2
4
(
e
n
d
o
f
s
t
u
d
y
)
2
(
1
0
)
4
(
2
0
)
0
(
0
)
0
(
0
)
T
o
t
a
l
(
s
u
m
o
f
a
l
l
s
t
u
d
i
e
s
)
b
4
5
c
4
(
9
)
6
(
1
3
)
0
(
0
)
0
(
0
)
S
e
r
u
m
s
a
m
p
l
e
s
f
r
o
m
p
l
a
c
e
b
o
-
c
o
n
t
r
o
l
l
e
d
a
r
m
o
f
o
n
e
P
h
a
s
e
1
d
o
s
e
-
f
i
n
d
i
n
g
s
t
u
d
y
a
n
d
t
w
o
P
h
a
s
e
3
s
t
u
d
i
e
s
w
e
r
e
e
v
a
l
u
a
t
e
d
f
o
r
a
n
t
i
b
o
d
i
e
s
t
o
r
o
m
i
p
l
o
s
t
i
m
a
n
d
T
P
O
.
I
n
c
i
d
e
n
c
e
o
f
a
n
t
i
b
o
d
i
e
s
w
a
s
e
x
p
r
e
s
s
e
d
a
s
a
p
e
r
c
e
n
t
a
g
e
a
n
d
d
e
r
i
v
e
d
f
r
o
m
n
u
m
b
e
r
o
f
s
u
b
j
e
c
t
s
p
o
s
i
t
i
v
e
f
o
r
a
n
t
i
-
r
o
m
i
p
l
o
s
t
i
m
o
r
T
P
O
/
t
o
t
a
l
n
u
m
b
e
r
o
f
s
u
b
j
e
c
t
s
f
o
r
a
p
a
r
t
i
c
u
l
a
r
s
t
u
d
y
.
a
P
l
a
c
e
b
o
s
u
b
j
e
c
t
s
w
e
r
e
c
o
n
s
i
d
e
r
e
d
p
o
s
i
t
i
v
e
f
o
r
p
r
e
-
e
x
i
s
t
i
n
g
a
n
t
i
b
o
d
i
e
s
i
f
t
h
e
y
w
e
r
e
p
o
s
i
t
i
v
e
a
t
t
h
e
p
r
e
-
d
o
s
e
o
r
p
o
s
t
-
d
o
s
e
t
i
m
e
-
p
o
i
n
t
.
b
T
o
t
a
l
i
n
c
i
d
e
n
c
e
w
a
s
e
x
p
r
e
s
s
e
d
a
s
a
p
e
r
c
e
n
t
a
g
e
a
n
d
d
e
r
i
v
e
d
f
r
o
m
n
u
m
b
e
r
o
f
s
u
b
j
e
c
t
s
p
o
s
i
t
i
v
e
f
o
r
t
h
e
r
e
l
e
v
a
n
t
a
n
t
i
-
r
o
m
i
p
l
o
s
t
i
m
o
r
a
n
t
i
-
T
P
O
a
n
t
i
b
o
d
y
/
t
o
t
a
l
n
u
m
b
e
r
o
f
s
u
b
j
e
c
t
s
e
n
r
o
l
l
e
d
.
c
O
f
t
h
e
4
5
s
u
b
j
e
c
t
s
i
n
t
h
e
p
l
a
c
e
b
o
-
d
o
s
e
d
g
r
o
u
p
,
3
5
s
u
b
j
e
c
t
s
r
o
l
l
e
d
o
v
e
r
i
n
t
o
t
h
e
o
n
g
o
i
n
g
l
o
n
g
-
t
e
r
m
e
x
t
e
n
s
i
o
n
s
t
u
d
y
a
n
d
w
e
r
e
d
o
s
e
d
f
o
r
t
h
e
f
i
r
s
t
t
i
m
e
i
n
t
h
i
s
s
t
u
d
y
.
H
e
n
c
e
,
o
n
l
y
t
e
n
p
l
a
c
e
b
o
-
d
o
s
e
d
s
u
b
j
e
c
t
s
r
e
m
a
i
n
e
d
a
t
t
h
e
t
i
m
e
o
f
a
n
a
l
y
s
i
s
.
Ann Hematol (2010) 89 (Suppl 1):S75–S85 S81kinetics of development of an immune response [21]. This
information could help to provide guidance to predict the
safety of these proteins during the clinical drug development
process and help make informed treatment decisions. A
sensitive SPR-based Biacore assay that was capable of
detecting both low and high affinity antibodies was used to
accomplish this approach.
Impact of binding and neutralizing antibodies on platelet
counts
The ability to maintain the platelet counts at 50 × 10
9/L or
above was used as a pharmacodynamic marker in two Phase
III clinical trials to establish the efficacy of romiplostim [17–
19]. Subjects that were positive for “pre-existing” or “post-
exposure” antibodies did not have an apparent effect on the
established platelet levels. One subject developed neutraliz-
ing antibody response against romiplostim. This subject
presented with a trend of lower platelet counts that coincided
with the development and maturation of the binding antibody
response from week 36 to week 79. The reduced platelet
count of 37 × 10
9/L at week 79/EOS could be attributed to
the presence of binding and neutralizing antibodies to
romiplostim. The platelet counts did not fall below baseline
(24 × 10
9/L) in this subject.
Characterization of antibody response
Antibodies to romiplostim and TPO were observed as early
as week 9 post-dose for some subjects and these antibodies
tended to persist for the duration of the study. Since the use
of concurrent immunosuppressive rescue medication was
markedly reduced in romiplostim-dosed subjects, immuno-
genicity assessment to romiplostim was not compromised.
It was not possible to determine if the initial use of
concurrent immunosuppressive medication could the de-
velopment of an immune response to romiplostim due to
low numbers of subject population who developed anti-
bodies. Both low and high affinity antibodies were
observed during the course of the clinical trials. The low
affinity binding antibodies to romiplostim observed in the
program did not impact the platelet profiles (data not
shown). Higher affinity antibodies were observed with the
maturation of the immune response; in one subject, such
antibodies potentially had an impact on enhanced drug
clearance. Epitope-mapping experiments indicated that
among the subjects who demonstrated post-exposure anti-
bodies to romiplostim, 70% were directed toward the TMP
peptide, the active site of the molecule. Further experiments
to characterize these antibodies showed that at least one
subject had neutralizing antibodies to romiplostim and that
these antibodies had been of the IgG1 isotype. These
observations on the characteristics of a mature antibody
response to romiplostim are consistent with our previous
experience with erythropoiesis-stimulating agents, where
high affinity, neutralizing antibodies directed towards the
active site of the molecule, correlate with efficacy.
Cross-reactivity with TPO
As the target receptors for both romiplostim and TPO are the
same in vivo, it was important to screen for antibodies cross-
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Fig. 2 Antibody incidence in ITP patients and healthy subjects across
clinical studies. a Pre-existing antibodies to romiplostim or TPO
include subjects who had binding antibodies prior to administration of
romiplostim. Some of these antibodies continued to persist even after
romiplostim dosing and were considered pre-existing. b Post-exposure
antibodies to romiplostim or TPO included subjects who had binding
antibodies following dosing with romiplostim. Serum samples from
healthy subjects that were a part of two initial Phase 1 studies were
evaluated for pre-existing and post-exposure binding antibodies to
romiplostim and TPO. The antibody incidence was compared to that
observed for ITP patients enrolled across ten clinical studies. ITP
patients had a higher incidence of pre-existing and post-exposure
antibodies to romiplostim as compared to the healthy subjects.
Similarly, ITP patients had a higher post-exposure incidence of anti-
TPO binding antibodies compared to healthy subjects
S82 Ann Hematol (2010) 89 (Suppl 1):S75–S85reactive with TPO. In previous clinical studies, administration
of multiple doses of another thrombopoietic agent, pegylated
recombinant human MGDF (PEG-rHuMGDF) to healthy
volunteers and cancer subjects resulted in development of
neutralizing antibodies to PEG-rHuMGDF that cross-reacted
withTPO.Some ofthesesubjects progressedtodevelopdrug-
induced autoimmune thrombocytopenia [6–8]. Romiplostim
has been designed such that it can bind to and signal through
the cMpl receptor, but has no amino acid sequence homology
to TPO [22]. Thus, the risk to subject’s development of
neutralizing antibodies against romiplostim was limited to a
loss of efficacy of the therapeutic protein. Our results support
∗∗ ↓ ↓ ↓
∗
↓
a
b
↓ δ δ
∗  
↓  
 
δ  
Fig. 3 a Platelet profiles and antibody status of a subject from the
roll-over extension study that developed neutralizing antibodies to
romiplostim are provided. Blood samples obtained at week 1 and
week 12 were negative for binding antibodies to romiplostim. At
week 36, week 60, and at week 66, blood samples were positive for
anti-AMG 531 binding antibodies and negative for anti-AMG 531
neutralizing antibodies, and yielded negative results. The subject
discontinued study at week 79 and the blood sample obtained at
week 79/end of study (EOS) was positive for anti-AMG 531 binding
antibodies and neutralizing antibodies. Single asterisks indicate
negative for anti-romiplostim binding antibodies. Down arrows
indicate positive for anti-romiplostim binding antibodies; negative
for anti-romiplostim neutralizing antibodies. Double down arrows
indicate positive for anti-romiplostim binding antibodies; positive for
anti-romiplostim neutralizing antibodies. b Platelet profiles and
antibody status of a subject from the roll-over extension study that
had pre-existing antibodies to TPO. Blood samples obtained at week 1,
week 9, week 17, and week 25 were assessed for antibodies to
romiplostim and TPO. Samples were negative for binding antibodies
to romiplostim at all time-points tested. The sample collected at pre-
dose time-point prior to exposure to romiplostim was positive for both
binding antibodies to TPO. Following dosing with romiplostim,
samples obtained at week 9 and week 17 were negative for antibodies
to TPO and positive for binding antibodies to TPO at week 25. No
obvious impact on platelets could be observed due to presence of
these pre-exposure neutralizing antibodies to TPO. Single asterisks
indicate negative for anti-romiplostim binding antibodies. Down
arrows indicate positive for anti-TPO binding antibodies; negative
for anti-TPO neutralizing antibodies. Double down arrows indicate
positive for anti-TPO binding antibodies; positive for anti-TPO
neutralizing antibodies. Delta indicates negative for anti-TPO binding
antibodies; negative for anti-TPO neutralizing antibodies
Ann Hematol (2010) 89 (Suppl 1):S75–S85 S83this concept in that none of the subjects administered
romiplostim developed anti-TPO neutralizing antibodies.
Association of autoimmune disease state to the pre-existing
and post-dose antibody development
The incidences of pre-existing and post-dose developing
antibodies to romiplostim and TPO were compared across
the placebo-dosed and romiplostim-dosed ITP and healthy
subjects. Pre-existing antibodies were evaluated in baseline
samples obtained from subjects prior to dosing. In the
clinical ITP program, the frequency of pre-existing anti-
bodies to romiplostim was 7% and to TPO was 5% in
romiplostim-dosed subjects (Table 2). A similar high
incidence of pre-existing antibodies was noted for the
placebo-dosed group of ITP subjects (9% for romiplostim
and 13% for TPO; Table 3). In contrast, the incidence of
pre-existing antibodies to romiplostim and TPO was 4%
and 2%, respectively, in the healthy subjects (Fig. 2).
This high incidence of pre-existing binding antibodies in
subjects with ITP could be attributed to the sensitive
Biacore screening assay that is capable of detecting low
affinity binding antibodies. In addition the autoimmune
disease state associated with ITP, could also contribute to
the higher incidence of pre-existing anti-romiplostim anti-
bodies in ITP subjects compared to healthy subjects. The
ITP subjects also presented a trend of higher immunoge-
nicity to romiplostim post-exposure to the drug (11% in ITP
subjects compared to 2% in healthy subjects). Similarly, the
incidence of anti-TPO binding antibodies was higher in ITP
subjects (5%) compared to healthy subjects (2%) post-
exposure to romiplostim. This observation suggests that the
autoimmune nature of ITP could be contributing to the
predisposition to elicit higher immunogenicity. In this
respect, pre-existing reactivity to TPO has been observed
in subjects with autoimmune conditions like ITP [23, 24]. It
is conceivable that molecular mimicry could account for
detection of these pre-existing antibodies [25, 26].
In conclusion, an immunogenicity assessment was per-
formed on all subjects treated with romiplostim during the
clinical development program in ITP, using sensitive assays to
detect binding and neutralizing antibodies. Although binding
antibodies were observed against romiplostim and TPO in
multiple subjects post-exposure to romiplostim, only one
subject was found positive for the presence of antibodies
capable of neutralizing romiplostim which may account for the
reduced platelet levels. The subjectwas eventually negativefor
neutralizing antibody response at the time of follow-up after
discontinuation of romiplostim. None of the subjects in the
study werepositivefor antibodiescapableofneutralizingTPO.
The limitation of this immunogenicity data is the relatively low
number of subjects evaluated in this orphan indication. When
evaluated in a larger cohort of subjects, the incidence of
romiplostim immunogenicity may be influenced by supportive
therapies,severityof disease states,andgeneticfactors.A post-
marketing surveillance program is in place to monitor subjects
for binding and neutralizing antibodies to address the risks and
limitations of the study described here.
Acknowledgments The authors would like to thank the following
individuals who have contributed significantly during the clinical
development of romiplostim over the years: Daniel Mytych, Eugene
Koren, Roger Craveiro, Erica Bramhall, and Janet Nichol. The authors
would also like to acknowledge the support of Michelle Zakson in the
finalization of the manuscript.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which permits
any noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
References
1. BusselJ,KuterD,GeorgeJ(2006)Romiplostim,athrombopoiesis-
stimulating protein, for chronic ITP. N Engl J Med 355:1672–1681
2. Kuter D (2007) New thrombopoietic growth factors. Blood
109:4607–4616
3. Bottiger L, Westerholm B (1972) Thrombocytopenia. Incidence
and aetiology. Acta Med Scand 191:535–540
4. Kelton J, Gibbons S (1982) Autoimmune platelet destruction:
idiopathic thrombocytopenic purpura. Semin Thromb Hemost
8:83–104
5. McMillan R (1981) Chronic idiopathic thrombocytopenic purpu-
ra. N Engl J Med 304:1135–1147
6. Li J, Yang C, Yea X (2001) Thrombocytopenia caused by the
development of antibodies to thrombopoietin. Blood 98:3241–3248
7. Crawford J, Glaspy J, Belani C (1998) A randomized, placebo-
controlled, blinded, dose-scheduling trial of pegylated recombi-
nant human megakaryocyte growth and development factor
(PEG-rHuMGDF) with Filgrastim support in non-small cell lung
cancer (NSCLC) patients treated with paclitaxel and carboplatin
during multiple cycles of chemotherapy [abstract]. Proc Am Soc
Clin Oncol 17:285
8. Basser R, O’Flaherty E, Green M, Edmonds M, Nichols J (2002)
Development of pancytopenia with neutralizing antibodies to
thrombopoietin after multicycle chemotherapy supported by mega-
karyocyte growth and development factor. Blood 99:2599–2602
9. Shankar G, Devanarayan V, Amaravadi L (2008) Recommenda-
tions for the validation of immunoassays used for detection of
host antibodies against biotechnology products. J Pharm Biomed
Anal 48:1267–1281
10. Gupta S, Indelicato S, Jethwa V (2007) Recommendations for the
design, optimization, and qualification of cell-based assays used
for the detection of neutralizing antibody responses elicited to
biological therapeutics. J Immunol Methods 32:1–18
11. Koren E, Smith H, Shores E (2008) Recommendations on risk-
based strategies for detection and characterization of antibodies
against biotechnology product. J Immunol Methods 333:1–9
12. Swanson S, Ferbas J, Mayeux P (2004) Evaluation of methods to
detect and characterize antibodies against recombinant human
erythropoietin. Nephron Clin Pract 96:88–95
13. Lofgren J, Dhandapani S, Pennucci J (2007) Comparing ELISA
and surface plasmon resonance for assessing clinical immunoge-
nicity of panitumumab. J Immunol 178:7467–7472
14. Mytych D, La S, Barger T, Ferbas J, Swanson S (2009) The
development and validation of a sensitive, dual-flow cell, SPR-
S84 Ann Hematol (2010) 89 (Suppl 1):S75–S85based biosensor immunoassay for the detection, semi-quantitation,
and characterization of antibodies to darbepoetin alfa and epoetin
alfa in human serum. J Pharm Biomed Anal 49:415–426
15. Safsten P (2009) Epitope mapping by surface plasmon resonance.
Methods Mol Biol 524:67–76
16. Sharon XM, Min X, Gary E (1995) Megakaryocyte growth and
development factor and interleukin-3 induce patterns of protein-
tyrosine phosphorylation that correlate with dominant differenti-
ation over proliferation of mpl-transfected 32D cells. Blood
86:4532–4543
17. Kuter D, Bussell J, Lyons R (2008) Efficacy of romiplostim in
patients with chronic immune thrombocytopenic purpura: a
double- blind randomized controlled trial. Lancet 371:395–403
18. Bussel J, Kuter D, Pullarkat V (2009) Safety and efficacy of long-
term treatment with romiplostim in thrombocytopenic patients
with chronic ITP. Blood 113:2161–2171
19. Shirasugi Y, Ando K, Hashino S (2009) A phase II, open-label,
sequential-cohort, dose-escalation study of romiplostim in Japa-
nese patients with chronic immune thrombocytopenic purpura. Int
J Hematol 90:157–165
20. George J, Mathias S, RS G (2009) Improved quality of life for
romiplostim-treated patients with chronic immune thrombocyto-
penic purpura: results from two randomized, placebo-controlled
trials. Br J Haematol 144:409–415
21. Swanson S (2006) Immunogenicity issues in drug development. J
Immunotoxicol 3:165–172
22. Broudy V, Lin N (2004) AMG 531 stimulates megakaryopoiesis
in vitro by binding to Mpl. Cytokine 25:52–60
23. Aledort L, Hayward C, Chen M, Nichol J, Bussel J (2004)
Prospective screening of 205 patients with ITP, including
diagnosis, serological markers, and the relationship between
platelet counts, endogenous thrombopoietin, and circulating
antithrombopoietin antibodies. Am J Hematol 76:205–213
24. Fureder W, Firbas U (2002) Serum thrombopoietin levels and
anti-thrombopoietin antibodies in systemic lupus erythematosus.
Lupus 11:221–226
25. Oldstone M (1998) Molecular mimicry and immune-mediated
diseases. Faseb J 12:1255–1265
26. Albert L, Inman R (1999) Molecular mimicry and autoimmunity.
N Engl J Med 34:2068–2074
Ann Hematol (2010) 89 (Suppl 1):S75–S85 S85